NUVB logo

Nuvation Bio Inc.

NUVB

NUVB: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

more

Show NUVB Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of NUVB by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by NUVB's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Heterocyclic compounds as bet inhibitors Feb. 21, 2023
  • Patent Title: Substituted pyrazolo[3,4-d]pyrimidines as wee1 inhibitors May. 17, 2022
  • Patent Title: Heterocyclic compounds as adenosine antagonists Apr. 19, 2022
  • Patent Title: Heterocyclic compounds and uses thereof Apr. 12, 2022
  • Patent Title: Diarylhydantoin compounds and methods of use thereof Apr. 05, 2022
  • Patent Title: 1,8-naphthyridinone compounds and uses thereof Feb. 22, 2022
  • Patent Title: Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors Dec. 07, 2021
  • Patent Title: Heterocyclic compounds as kinase inhibitors Nov. 16, 2021
  • Patent Title: Pyrrole and pyrazole compounds and methods of use thereof Jun. 15, 2021
  • Patent Title: Heterocyclic compounds as adenosine antagonists Jun. 08, 2021
  • Patent Title: Heterocyclic compounds and uses thereof Oct. 20, 2020
  • Patent Title: 1,8-naphthyridinone compounds and uses thereof Oct. 06, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of NUVB in WallStreetBets Daily Discussion

NUVB News

Recent insights relating to NUVB

CNBC Recommendations

Recent picks made for NUVB stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NUVB

Corporate Flights

Flights by private jets registered to NUVB